Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 2/20 | 0.47 |
| ▸ | TTK | P33981 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.46 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.44 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.44 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.44 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | PTK2 | Q05397 | 11/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
| ▸ | AXL | P30530 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4507560 | 0.92 | LCK (0.46) | ITKLCKJAK3BTKTNK2 | |
| SCHEMBL4489728 | 0.92 | LCK (0.47) | LCKJAK3BTKTNK2MET | |
| SCHEMBL4497267 | 0.91 | AXL (0.51) | TTKLCKJAK3BTKTNK2 | |
| SCHEMBL5686360 | 0.91 | LCK (0.47) | ITKLCKJAK3BTKTNK2 | |
| SCHEMBL4496650 | 0.90 | LCK (0.54) | ITKLCKJAK3BTKTNK2 | |
| SCHEMBL4500830 | 0.89 | LCK (0.47) | LCKJAK3BTKTNK2MET | |
| SCHEMBL4497902 | 0.87 | AXL (0.51) | TTKLCKJAK3BTKTNK2 | |
| SCHEMBL4492554 | 0.87 | LCK (0.48) | LCKJAK3BTKTNK2MET | |
| SCHEMBL4498752 | 0.86 | PTK2 (0.48) | TTKLCKJAK3BTKTNK2 | |
| SCHEMBL4495901 | 0.86 | MET (0.47) | LCKJAK3BTKTNK2MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-09-22 | — | — | US | claimed |
| US-7504396-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | ICOS, CD4, HLA-DRB1 | ITK 3373/4885TTK 3470/4885LCK 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.